SomaLogic stock (US82489T1043): Completed $350M sale to Illumina

Standard BioTools Inc. completed the sale of its SomaLogic subsidiary to Illumina Inc. for $350 million on January 30, 2026. The transaction, announced earlier, enhances Standard BioTools' balance sheet and supports its strategic pivot toward proteomics and multiomics technologies. SomaLogic, known for its SomaScan proteomics platform, was a key asset in the deal, as reported by GlobeNewswire as of 01/30/2026 and MarketBeat as of 01/30/2026.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

SomaLogic: core business model

SomaLogic Inc. specialized in proteomics through its proprietary SomaScan platform, which measures thousands of proteins from small sample volumes using aptamer-based technology. The company provided omics laboratory services, including genomics, proteomics, and bioinformatics, targeting pharmaceutical research and diagnostics. Prior to the acquisition, SomaLogic held a 0.1% market share in the omics lab services sector, according to EINPresswire as of 05/12/2026.

The business model focused on high-throughput protein biomarker discovery, serving drug developers and clinical researchers. Integration into Standard BioTools expanded its multiomics capabilities before the divestiture to Illumina.

Main revenue and product drivers for SomaLogic

Key revenue came from SomaScan assays, enabling proteomic profiling for over 7,000 proteins, used in drug discovery and disease research. Services extended to custom omics projects, with clients in biotech and pharma. The platform's scalability drove demand in precision medicine, contributing to SomaLogic's position among top omics providers.

In the competitive landscape, SomaLogic competed with Labcorp, Thermo Fisher, and Eurofins, as noted in recent market analyses. The sale to Illumina bolsters the buyer's multiomics portfolio, including next-generation sequencing synergies.

Industry trends and competitive position

The omics lab services market features leaders like Labcorp Holding Inc. (1% share), Thermo Fisher Scientific Inc. (1%), and Charles River Laboratories (1%). SomaLogic's niche in proteomics positioned it alongside BGI Genomics and Novogene. Trends toward integrated multiomics data analysis favor platforms like SomaScan, per EINPresswire data published May 12, 2026.

Why SomaLogic matters for US investors

For US investors, SomaLogic's technology underscores innovation in biotech, with exposure via Nasdaq-listed Standard BioTools (LAB). The $350 million deal highlights M&A activity in genomics, relevant to portfolios tracking life sciences growth amid US healthcare spending.

Conclusion

The completion of SomaLogic's $350 million sale to Illumina marks a pivotal transaction for Standard BioTools, freeing capital for core growth areas. Investors monitor how proceeds will fund proteomics advancements amid competitive omics dynamics. Market positions and tech synergies remain key focal points.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.